英雄联盟s10投注


LOL下注网站

 

Year-end webcast for investors and analysts on China and Emerging Markets英雄联盟s10投注

On 13 December 2018, we hosted a webcast for investors and analysts on China and Emerging markets.


LOL下注网站

We have a three-pillar strategy in Emerging Markets, which was originally built upon the China strategy of Expansion, Innovation and Partnership.英雄联盟s10投注


  • Market access is especially critical to expansion, so we can reach more patients with our medicines in previously-inaccessible countries.
  • Regarding innovation, our aim is to strongly contribute to patient-centric, fully-integrated ecosystems. We also aim to discover and develop new medicines in Emerging Markets that are fit for our patient populations in those markets.
  • Partnership is more than just a word or intention – at AstraZeneca we proactively work with local and central governments and local partners.  We also work closely with local healthcare providers and local capital markets where possible.

 


LOL下注网站


英雄联盟s10投注

英雄联盟s10投注

英雄联盟s10投注

英雄联盟s10投注

英雄联盟s10投注

英雄联盟s10投注

英雄联盟s10投注

英雄联盟s10投注


We are proud to be present in China for over 26 years now. We have invested, and continue to invest, in local R&D and manufacturing in Taizhou and Wuxi.英雄联盟s10投注

We are the number two multinational in China, AstraZeneca’s second-largest market globally. Importantly, we’ve been growing faster than any other multinational company in China for several years.英雄联盟s10投注